News and Trends 28 Sep 2017 Study Results Confirm that Abivax’s Treatment Towards an HIV Cure Gets Rid of Virus Abivax’s HIV cure candidate, ABX464, caused a significant drop in the viral reservoir over an extended period during a Phase IIa study. Abivax targets the immune system to cure viral diseases. The company has announced initial results from the first cohort of patients in its most recent Phase IIa trial testing its potential HIV cure, ABX464. Initial […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 German Researchers’ Algorithm Can Predict New Targets for Existing Drugs An algorithm based on the brain’s self-organizing capacity has been developed in Germany that could combat the rising costs of drug development. A team at TU Dresden has pioneered an algorithm that exploits the self-organization of the brain to predict new drug targets, without the need for extra biological or molecular information. The study, published in Briefings […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 French Gene Therapy for Wilson’s Disease gets Orphan Status Vivet Therapeutics has been granted Orphan Drug Designation for its gene therapy for Wilson’s disease, VTX-801, by both the FDA and the European Commission. The French biotech Vivet Therapeutics is developing what could eventually become the first gene therapy for Wilson’s disease. Seeing its potential, both the FDA and the EC have decided to grant […] September 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU Janssen’s single-tablet regimen, Symtuza, has been approved by the European Commission for the treatment of HIV in adults and adolescents in the EU. The pharmaceutical arm of Johnson & Johnson, Janssen, has announced that the European Commission has approved its single-tablet regimen (STR), Symtuza, to treat Human Immunodeficiency Virus (HIV) infections. Previous studies have demonstrated […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 New British Spin-Out Wants to Replace Hormonal Menopause Treatment KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […] September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at both hematological cancers and solid tumors. The Series C fundraising of $80M (€68M) is added to £70M (€80M) made in Series A […] September 26, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […] September 26, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […] September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2017 Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix mRNA cancer therapies. eTheRNA has been awarded the €1M industrial R&D projects grant by Flanders Innovation and Entrepreneurship. The company’s technology uses mRNA that stimulates the immune system to effectively treat cancer, giving rise to long-lasting remission in patients. It will […] September 25, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2017 Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains Sanofi, in collaboration with the US National Institute of Health, is developing an antibody HIV treatment that can kill 99% of strains. Human immunodeficiency virus (HIV) is notoriously difficult to treat as it mutates so quickly. Some patients develop ‘broadly neutralizing antibodies’ that attack fundamental parts of the virus, and are therefore very powerful tools. Researchers […] September 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2017 BioArt and Bacteria Exhibition is Coming to Oxford A new exhibition in Oxford features the beautiful art of Anna Dumitriu, exploring the complex world of microbes and how we interact with them. Anna Dumitriu, prolific bioartist that works with bacteria, will show some of her best work at the solo exhibition BioArt and Bacteria that will be hosted at the Museum of the […] September 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2017 EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance Da Volterra has been boosted by a €20M loan to speed up the development of solutions for the antibiotic resistance crisis. The French biopharma concentrates on the prevention and treatment of serious infections. This is a big area of interest due to rapidly rising antibiotic resistance. The company has been boosted by a €20M loan from the […] September 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email